Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975

Published: Aug. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Language: Английский

---

Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion

Biology, Journal Year: 2024, Volume and Issue: 13(5), P. 307 - 307

Published: April 28, 2024

Cancer immune evasion represents a leading hallmark of cancer, posing significant obstacle to the development successful anticancer therapies. However, landscape cancer treatment has significantly evolved, transitioning into era immunotherapy from conventional methods such as surgical resection, radiotherapy, chemotherapy, and targeted drug therapy. Immunotherapy emerged pivotal component in treatment, harnessing body’s system combat offering improved prognostic outcomes for numerous patients. The remarkable success spurred efforts enhance clinical efficacy existing agents strategies. Several immunotherapeutic approaches have received approval treatments, while others are currently preclinical trials. This review explores recent progress unraveling mechanisms evaluates effectiveness diverse strategies, including vaccines, adoptive cell therapy, antibody-based treatments. It encompasses both established treatments those under investigation, providing comprehensive overview through immunological approaches. Additionally, article emphasizes current developments, limitations, challenges immunotherapy. Furthermore, by integrating analyses resistance exploring combination strategies personalized approaches, it offers valuable insights crucial novel

Language: Английский

---

Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 4533 - 4568

Published: May 1, 2024

Until now, there has been a lack of effective strategies for cancer treatment. Immunotherapy high potential in treating several cancers but its efficacy is limited as monotherapy. Chemoimmunotherapy (CIT) holds promise to be widely used Therefore, identifying their involvement and synergy CIT approaches decisive. Nano-based drug delivery systems (NDDSs) are ideal because they can simultaneously target immune cells cells, promoting accumulation, reducing the toxicity drug. In this review, we first introduce five current immunotherapies, including checkpoint blocking (ICB), adoptive cell transfer therapy (ACT), vaccines, oncolytic virus (OVT) cytokine therapy. Subsequently, immunomodulatory effects chemotherapy by inducing immunogenic death (ICD), tumor killer infiltration, down-regulating immunosuppressive inhibiting checkpoints have described. Finally, NDDSs-mediated collaborative introduced detail, development nanoparticles prospected.

Language: Английский

---

Advances in preclinical and clinical studies of oncolytic virus combination therapy

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 7, 2025

Oncolytic viruses represent a distinct class of that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic encounter several challenges as standalone therapies. Consequently, the combination with other therapeutic modalities has emerged prominent research focus. This paper summarizes tumor-killing mechanisms viruses, explores integration radiotherapy, chemotherapy, immune checkpoint inhibitors, CAR-T, CAR-NK therapies, provides an overview related clinical trials. By synthesizing these advancements, this study seeks to offer valuable insights for translation virus

Language: Английский

---

Herpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery

World Neurosurgery, Journal Year: 2025, Volume and Issue: 194, P. 123595 - 123595

Published: Jan. 23, 2025

The authors present a comprehensive review on the history and development of oncolytic herpes simplex viral therapies for malignant glioma with focus mechanisms delivery in prior ongoing clinical trials. This highlights advancements made regard to delivering these highly complex immunologic environment setting blood brain tumor barrier safe effective manner.

Language: Английский

---

Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: July 2, 2024

Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying a substantial global health burden. While considerable progress has been made recent years through the emergence of immunotherapy modalities, such as immune checkpoint inhibitors (ICIs), monotherapies often yield limited clinical outcomes. The rationale behind combining various immunotherapeutic or other anticancer agents, mechanistic underpinnings, and evidence supporting their utilization is crucial NSCLC therapy. Regarding synergistic potential combination immunotherapies, this study aims to provide insights help landscape treatment improve In addition, review article discusses challenges considerations regimens, including toxicity management patient selection.

Language: Английский

---

Epigenetic modulation by oncolytic viruses: Implications for cancer therapeutic efficacy

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189270 - 189270

Published: Jan. 1, 2025

Language: Английский

---

Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review

Pathogens, Journal Year: 2025, Volume and Issue: 14(2), P. 140 - 140

Published: Feb. 3, 2025

Ovarian cancer (OC) remains the most lethal gynecologic malignancy with limited effective treatment options. Oncolytic viruses (OVs) have emerged as a promising therapeutic approach for treatment, capable of selectively infecting and lysing cells while stimulating anti-tumor immune responses. Preclinical studies demonstrated significant tumor regression prolonged survival in OC models using various OVs, such herpes simplex. Early-phase clinical trials shown favorable safety profile, though impact on patient has been modest. Current research focuses combining OVs other treatments like checkpoint inhibitors to enhance their efficacy. We provide comprehensive overview current understanding future directions utilizing management OC.

Language: Английский

---

Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 715 - 715

Published: Feb. 20, 2025

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with poor prognosis. Currently, chemotherapy the only option for most patients advanced-stage PDAC. Further, conventional immunotherapies and targeted therapies improve survival outcomes in rare PDAC patient subgroups. To date, combinatory immunotherapeutic strategies to overcome immune-hostile tumor microenvironment (TME) have resulted limited efficacy clinical studies. However, efforts are ongoing develop new treatment evolving knowledge of TME, molecular characterization, immune resistance mechanisms. growing arsenal various agents, including novel classes checkpoint inhibitors oncolytic, chimeric antigen receptor T cell, vaccine therapies, reinforces these efforts. This review will focus on place immunotherapy future possible

Language: Английский

---

Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2167 - 2167

Published: Feb. 28, 2025

Due to the minimal survival benefits of existing therapies for pediatric diffuse midline glioma (DMG) patients, new therapeutic modalities are being investigated. Immunotherapies such as CAR-T cells and oncolytic viruses (OVs) part these efforts, evidenced by increasing number clinical trials. αβ T engineered with a high-affinity γ9δ2 T-cell receptor (TEGs) immune designed target metabolic changes in malignant or virally infected via BTN2A1 BTN3A. Because expression BTN3A can be altered tumor cells, combining TEGs OVs could potentially enhance anti-tumor response. We investigated this hypothesis following study. demonstrate that indeed DMG, which expresses at varying levels, further BTN3A-but not BTN2A1-in DMG. Functionally, killed DMG cell cultures, killing was increased after OV infection DMGs either adenovirus Δ24-RGD reovirus R124 under suboptimal conditions. However, additive effect lost when TCR-ligand interaction boosted pamidronate. This study demonstrates Vγ9Vδ2 TCR-engineered conditions supports combination strategy efficacy both modalities.

Language: Английский

---